Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

ing pipeline of products, which will be validated in the clinic using the proceeds of this financing round," said Sander Slootweg, managing partner at Forbion Capital Partners. "We are delighted to invest in Fovea Pharmaceuticals and join an experienced and proven management team along with a very strong and committed group of investors."

In connection with the financing, Sander Slootweg will join the Board of Directors which is comprised of Antoine Papiernik (Sofinnova Partners), Tim Haines (Abingworth), Anthony Wild (Bows Pharmaceuticals) and Bernard Gilly. Bernard Gilly has been elected as Chairman of the Board.

"Fovea's unique product platform has led to the generation of a robust pipeline of promising therapeutic candidates for the treatment of front and back of the eye disorders. Clinical candidates are already in development and at least three new products are expected to progress into the clinic in 2008," commented Pr. Jose-Alain Sahel, Founder of Fovea Pharmaceuticals and Chairman of the Scientific Advisory Board. "It has been a pleasure to work with the talented and productive team at Fovea, and we all look forward to continued progress in exploiting the potential of these novel dedicated therapies."

In parallel to these clinical developments, a strong discovery platform has been implemented, leading to the identification of novel targets. Fovea Pharmaceuticals has recently signed a Research Partnership Agreement with Genzyme to develop gene related therapies on the basis of one of these programs, using Fovea's selected targets to treat major retinal dystrophies.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Created in May 2005, Fovea has a highly experienced board and management team. Fovea has been funded by six leading E
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/15/2014)... Dec. 15, 2014 Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology,  today ... collaborators of its exVive3D TM Human Liver ... in full commercial release on November 18, has ... in several awards for innovation. Most ...
(Date:12/13/2014)... 2014 /CNW/ - MaRS and Virgin Unite Canada, the non-profit ... joined forces to support Canadian entrepreneurs tackling social and environmental ... was at the MaRS Centre to announce the new partnership, ... fund. This fund has $1 million in seed capital provided ... -based Mindset Social Innovation Foundation, founded by Alison Lawton ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... CAMBRIDGE, Massachusetts, February 20, Shire plc (LSE: SHP, ... company, announced today that it has officially,opened a ... Soh Fujiwara as,Managing Director for Japanese operations. , ... Shinkujuku Ward, Tokyo, will serve as the base ...
... Sciences presented important new results on the continued ... HIV-1 at the 16th Conference on Retroviruses and ... focused on the results of IND-directed development of ... formulation of IQP-0528 as a topical microbicide to ...
... Inc. (Nasdaq: ITMN ) announced today that it ... Thursday, February 26, 2009 at 4:00 p.m. Eastern time. ... InterMune at 4:30 p.m. Eastern time that same day. , ... (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access ...
Cached Biology Technology:Shire Announces Opening of Office in Japan 2Shire Announces Opening of Office in Japan 3ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 2ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 3InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26 2
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... at Yale provided a glimpse of the ancient mechanism ... between gene processing in humans and the most primitive ... crucial self-splicing region of RNA. Genes of higher ... molecules. But, after transcription from the DNA, these RNAs ...
... at UT Southwestern Medical Center have developed a simple ... pull out a handful that might treat cancer and ... one screen of more than 300,000 such molecules, called ... candidates that mimicked an antibody already on the market ...
... Research present in a forthcoming issue of the International ... dental implants with a synthetic bone material prior to ... successfully into the jaw, leading to smiles all round. ... dental and medical implants. However pure titanium has a ...
Cached Biology News:Yale scientists visualize the machinery of mRNA splicing 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 3Crowning glory 2
... Software reads and processes raw ... microarray data for analysis. ... one 1-year license for Feature ... ,one CD-ROM containing Feature Extraction ...
... CHEMICONs ELF 97 Cytological Labeling Kit provides ... the detection of cellular targets, including cell-surface ... Cytological Labeling Kit contains the patented ELF ... fluorescent yellow-green precipitate at the site of ...
... Many differences exist between the various commercial ... glass slide used, the length and GC ... and the manufacturing protocol employed all influence ... analysis. With all the different variables ...
... SYBR Safe DNA Gel Stain combo offers these benefits: ... these same products separately ... Eliminates risks to yourself, ... RNA fragments from 100 bp to >30 kb. UltraPure ...
Biology Products: